Spruce Biosciences (SPRB) Announces Topline Results from CAHmelia-203
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- European shares subdued as surging crude sharpens focus on ECB rate path
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Spruce Biosciences, Inc. (SPRB) PT Lowered to $4 at Oppenheimer
March 14, 2024 9:11 AM EDTOppenheimer analyst Hartaj Singh lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $4.00 (from $7.00) while maintaining a Outperform rating.
The analyst comments "Spruce (SPRB) announced top-line results from the CAHmelia-203 and CAHptain-205 studies of tildacerfont in adult and pediatric classic CAH,... More
Spruce Biosciences (SPRB) Halted, News Pending
March 13, 2024 4:02 PM EDTSpruce Biosciences (NASDAQ: SPRB) Halted, News Pending
